BÖLÜM 11

KALP YETERSİZLİĞİNDE SODYUM-GLUKOZ KO-TRANSPORTER 2 İNHİBİTÖRLERİ

Yasin ÖZEN[1]

GİRİŞ

Sodyum Glukoz Ko-transporter 2 (SGLT2) İnhibitörleri geçtiğimiz dekatta antidiyabetik olarak hayatımıza giren ilaçlardır. Dünya sağlık Örgütü (DSÖ) 2008 yılında; tiazolidindion grubu ilaçların kardiyak sonlanımları olumsuz olmasından dolayı,[1,2] Diabetus Mellitus (DM) ilaçlarının kardiyak sonlanımlarının araştırılması için kurallar getirdi. Öyle ki piyasaya çıkacak bir antidiyabetik ajanın kardiyovasküler güvenliliğinin araştırılması gerekmektedir. Günümüze kadar kardiyovasküler (KV) sonlanımları olumlu sonuçlanan antidiyabetik saptanmamıştır. Ta ki bu durum yeni oral antidiabetik ajanlar olan SGLT2 inhibitörlerinin kardiyak sonlanımları olumlu sonuçlanması ile son bulmuştur.

ETKİ MEKANİZMASI

Sodyum Glukoz Ortak Taşıyıcılar (SGLT)

Günümüzde bilinen bulundukları yer ve özelliklerine göre ayrılan 7 tip SGLT vardır (Tablo 1).[3] Böbrekte en yaygın bulunan taşıyıcı ise proksimal tübülün S1 ve S2 segmentinde yer alan SGLT2'dir.

Sağlıklı bir insanda 180 gr. glukoz filtrat olarak süzülür. Renal glukoz reabsorbsiyonunun yaklaşık %80-90'ı proksimal tübülde SGLT2 ile gerçekleşir. Glomerüler filtrattaki sodyum (Na) ve glukoz 1:1 oranda (sodyum: glukoz) SGLT2 aracılığıyla proksimal tübül hücrelerine emilir. Hücre içine geçen glukoz GLUT2 taşıyıcıları ile

[1] Uzm. Dr., Sivas Numune Hastanesi, Kardiyoloji Bölümü, ysnozn70@gmail.com

2022 ACC/AHA toplantısında SGLT2i' lerinin çalışmaları konuşulmuş ve Nisan ayından yayınlanan KY yönetimi kılavuzunda yerini almıştır. Bu kılavıza göre Tip 2 diyabetli ve yerleşik KV hastalığı olan veya yüksek kardiyovasküler riski olan hastalarda (Evre A KY), KY nedeniyle hastaneye yatışları önlemek için SGLT2i kullanılmalıdır. (Sınıf 1 Kanıt Düzeyi A)[58]

Sonuç olarak üç büyük KV sonlanım çalışmalarına, DEF- KY ve KEF- KY çalışmalarına bakıldığında ve daha önemlisi bu çalışmalar sonrası yapılan metaanalizlere bakıldığında SGLT2i' lerinin; KV hastalıkları önlemede ve tedavide vazgeçilmez bir tedavi seçeneği olduğu gerçektir. Farklı ve daha spesifik hasta gruplarında sürmekte olan ve gelecekte yapılacak olan çalışmalar bu moleküllerin yüzyılı aşkın tarihteki yolculuğuna ışık tutacaklardır.

KAYNAKLAR

1. Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. Journal of the American College of Cardiology. 2007;49(16):1696-704.
2. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet (London, England). 2015;385(9982):2107-17.
3. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. Journal of internal medicine. 2007;261(1):32-43.
4. Chin E, Zhou J, Bondy C. Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. The Journal of clinical investigation. 1993;91(4):1810-5.
5. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Archiv : European journal of physiology. 2004;447(5):510-8.
6. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes, obesity & metabolism. 2009;11(2):79-88.
7. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. The Journal of clinical investigation. 1987;79(5):1510-5.
8. Wright EM. I. Glucose galactose malabsorption. The American journal of physiology. 1998;275(5):G879-82.
9. Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. Journal of medicinal chemistry. 2009;52(7):1785-94.
10. Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovascular diabetology. 2018;17(1):144.
11. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes care. 2016;39(7):1108-14.
12. Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences. 2016;93:244-52.
13. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine. 2015;373(22):2117-28.
14. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England journal of medicine. 2020;383(15):1413-24.

15. Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, et al. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. European journal of heart failure. 2019;21(7):932-42.
16. Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, et al. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. JAMA Cardiology. 2021;6(7):836-40.
17. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine. 2021;385(16):1451-61.
18. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England journal of medicine. 2017;377(7):644-57.
19. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine. 2019;380(4):347-57.
20. Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, Hashimoto T, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. Journal of gastroenterology. 2018;53(1):140-51.
21. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England journal of medicine. 2019;380(24):2295-306.
22. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine. 2019;381(21):1995-2008.
23. Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019;140(18):1463-76.
24. Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European journal of heart failure. 2021;23(7):1217-25.
25. Taylor SI, Blau JE, Rother KI, Beitelshees AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. The lancet Diabetes & endocrinology. 2019;7(12):949-58.
26. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England journal of medicine. 2021;384(2):129-39.
27. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England journal of medicine. 2021;384(2):117-28.
28. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. The New England journal of medicine. 2020;383(15):1425-35.
29. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MAJTlD, endocrinology. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. 2014;2(10):843-51.
30. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes, obesity & metabolism. 2013;15(5):403-9.
31. Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2016;93:244-52.
32. Koepsell H. The Na(+)-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & therapeutics. 2017;170:148-65.
33. Kusunoki M, Natsume Y, Sato D, Tsutsui H, Miyata T, Tsutsumi K, et al. Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes. Drug research. 2016;66(11):603-6.

34. Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. American journal of physiology Renal physiology. 2014;307(3):F317-25.
35. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PloS one. 2014;9(6):e100777.
36. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. The New England journal of medicine. 2016;375(4):323-34.
37. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. The lancet Diabetes & endocrinology. 2018;6(9):691-704.
38. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. The lancet Diabetes & endocrinology. 2019;7(8):606-17.
39. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2020;35(10):1700-11.
40. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine. 2020;383(15):1436-46.
41. Packer M. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors. Journal of the American Society of Nephrology : JASN. 2020;31(5):907-19.
42. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. European heart journal. 2016;37(19):1526-34.
43. Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. Journal of the American Heart Association. 2018;7(4).
44. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2019;21(2):137-55.
45. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England). 2019;393(10166):31-9.
46. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819-29.
47. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism. 2017;19(3):348-55.
48. Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ (Clinical research ed). 2018;363:k4365.
49. Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862-72.

50. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. The lancet Diabetes & endocrinology. 2015;3(1):8-10.
51. Steen O, Goldenberg RM. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. Canadian journal of diabetes. 2017;41(5):517-23.
52. Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA internal medicine. 2018;178(9):1190-8.
53. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European heart journal. 2020;41(2):255-323.
54. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
55. Çavuşoğlu Y, Altay H, Cahn A, Celik A, Demir S, Kılıçaslan B, et al. Sodium glucose co-transporter 2 inhibitors in heart failure therapy. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir. 2020;48(3):330-54.
56. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2022;24(1):4-131.
57. McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. 2021;37(4):531-46.
58. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022:101161cir0000000000001063.